– MaxQ AI and Blackford today announced that MaxQ AI’s FDA-cleared and CE Marked ACCIPIO ICH applications for stroke, traumatic brain injury and head trauma are now available on the Blackford Platform.
– Fully integrated with existing systems, the Blackford Platform simplifies the implementation and management of multiple imaging applications and AI algorithms and reduces the load on PACS.
– MaxQ AI now has distribution agreements in place with trusted CT OEMs, PACS software, and AI Ecosystem companies – including Philips, GE Healthcare, IBM Watson Health, Samsung Neurologica, Nuance, TeraRecon, Blackford, and Arterys.
Blackford, the centralized medical imaging platform announced that MaxQ AI’s FDA-cleared and CE Marked ACCIPIO ICH applications for stroke, traumatic brain injury, and head trauma are now available on the Blackford Platform.
Developed by MaxQ AI, the Accipio solutions use artificial intelligence in the assessment of non-contrast head CT images for suspected intracranial hemorrhage (ICH). Accipio Ix is intended for identification and prioritization, while Accpio AxTM also includes slice-level annotation.
Economic Cost of a Missed ICH
The cost of a missed ICH can be significant, but the economic cost of treating a misdiagnosed patient is nothing compared to the devastation to families and loved ones. Even being able to divert only one patient per year to wellness from stroke care represents a significant saving for a hospital and makes a lifetime of difference to patients and their families.
Fully integrated with existing systems, Blackford Platform simplifies the implementation and management of multiple imaging applications and AI algorithms, and reduces load on PACS. New applications can easily be added to the image-processing platform, reducing implementation time, costs, and long-term maintenance.
Why It Matters
“Our partnership with Blackford will expand access to our innovative AI-powered ICH solutions for stroke, TBI, and head trauma to radiologists and care providers worldwide, who trust Blackford as a valued partner to deliver quality solutions,” said Gene Saragnese, CEO at MaxQ AI. “We view this as a powerful collaboration that will bridge the technology divide to enable more and more hospitals and healthcare organizations to seamlessly integrate our ACCIPIO® platform.”
MaxQ AI now has distribution agreements in place with trusted CT OEMs, PACS software, and AI Ecosystem companies – including Philips, GE Healthcare, IBM Watson Health, Samsung Neurologica, Nuance, TeraRecon, Blackford and Arterys.
